ningetinib   Click here for help

GtoPdb Ligand ID: 11624

Synonyms: CT-053 | CT053 | CT053PTSA | Example 1 [US9133162]
Compound class: Synthetic organic
Comment: Ningetinib (CT053) is an oral small molecule multiple tyrosine kinase inhibitor. It inhibits c-Met, VEGFR2, Axl, Mer, RON and FLT3.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 2
Rotatable bonds 9
Topological polar surface area 107.09
Molecular weight 556.21
XLogP 4.04
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES Fc1cc(ccc1Oc1ccnc2c1ccc(c2)OCC(O)(C)C)NC(=O)c1c(C)n(n(c1=O)c1ccccc1)C
Isomeric SMILES Fc1cc(ccc1Oc1ccnc2c1ccc(c2)OCC(O)(C)C)NC(=O)c1c(C)n(n(c1=O)c1ccccc1)C
InChI InChI=1S/C31H29FN4O5/c1-19-28(30(38)36(35(19)4)21-8-6-5-7-9-21)29(37)34-20-10-13-27(24(32)16-20)41-26-14-15-33-25-17-22(11-12-23(25)26)40-18-31(2,3)39/h5-17,39H,18H2,1-4H3,(H,34,37)
No information available.
Summary of Clinical Use Click here for help
Ningetinib (CT053) has progressed to clinical evaluations in solid tumours and haematological malignancies.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03915184 Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2) Phase 1 Interventional Carsgen Therapeutics, Ltd.
NCT03758287 Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative Phase 1/Phase 2 Interventional Sunshine Lake Pharma Co., Ltd.
NCT04577703 First-In-Human Phase I Trial of Ningetinib ( CT053PTSA ) in the Patients With Advanced Solid Tumors Phase 1 Interventional Sunshine Lake Pharma Co., Ltd.